Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis

医学 养生 中性粒细胞减少症 顺铂 白细胞减少症 紫杉醇 化疗 内科学 转移 胃肠病学 癌症 发热性中性粒细胞减少症 毒性 肿瘤科
作者
Daisuke Kobayashi,Hironori Ishigami,Mitsuro Kanda,Chie Tanaka,Hironori Yamaguchi,Joji Kitayama,Yasuhiro Kodera
出处
期刊:Oncology [Karger Publishers]
卷期号:98 (1): 48-52 被引量:6
标识
DOI:10.1159/000502484
摘要

<b><i>Introduction:</i></b> Intraperitoneal (IP) chemotherapy is a promising treatment option for gastric cancer (GC) with peritoneal metastasis (PM). Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis. Thus, attempts to combine IP PTX with other systemic therapies with higher efficacy are warranted. We designed a new regimen combining IP PTX with S-1 plus cisplatin (SP), which is regarded as the standard first-line treatment for metastatic GC in Japan, and subsequently carried out a dose-escalation study. <b><i>Methods:</i></b> The combination was a 5-weekly regimen. IP PTX was to be administered on days 1, 8, and 22 with an initial dose of 15 mg/m<sup>2</sup> at level 1 and 20 mg/m<sup>2</sup> at level 2. S-1 was to be administered orally at a fixed dose of 80 mg/m<sup>2</sup> b.i.d. for 21 days followed by a ­14-day rest. Cisplatin was to be administered intravenously at a dose of 60 mg/m<sup>2</sup> on day 8. Dose-limiting toxicities (DLTs) were defined as grade 4 leukopenia, grade 3 (G3) febrile neutropenia, G3 thrombocytopenia, and G3 nonhematological toxicity. <b><i>Results:</i></b> A total of 9 patients with macroscopic PM were enrolled. No DLTs were observed among the 3 patients at level 1 and 6 patients at level 2. No adverse events or technical problems associated with the IP administration were observed. Consequently, the maximum-tolerated dose was not reached, and the dose for further clinical trials of IP PTX was determined as 20 mg/m<sup>2</sup>. As for efficacy, peritoneal lavage cytology turned negative after the first course in 4 of 7 patients who had positive cytology before treatment. <b><i>Conclusion:</i></b> The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m<sup>2</sup>, when combined with the 5-weekly SP regimen.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
无钱发布了新的文献求助10
1秒前
1秒前
桐桐应助dddd采纳,获得10
1秒前
亚七发布了新的文献求助10
1秒前
2秒前
2秒前
熊猫盖浇饭完成签到,获得积分10
2秒前
又又完成签到,获得积分20
2秒前
3秒前
宋思薇发布了新的文献求助10
4秒前
ZIYU完成签到,获得积分10
4秒前
湛恩梅完成签到,获得积分10
5秒前
SR发布了新的文献求助10
5秒前
刘亚梅发布了新的文献求助10
6秒前
又又发布了新的文献求助10
6秒前
7秒前
7秒前
陈__发布了新的文献求助10
8秒前
廖怡星发布了新的文献求助10
9秒前
13发布了新的文献求助10
9秒前
CodeCraft应助一一采纳,获得10
10秒前
SR完成签到,获得积分10
10秒前
少年啊完成签到,获得积分10
12秒前
SciGPT应助灵巧的觅柔采纳,获得10
13秒前
mmiww发布了新的文献求助10
13秒前
13秒前
14秒前
所所应助陈__采纳,获得10
14秒前
15秒前
香豆素完成签到 ,获得积分10
15秒前
好久不见完成签到,获得积分10
16秒前
透明人完成签到,获得积分10
16秒前
苹果夜梦完成签到 ,获得积分10
17秒前
haozaizai完成签到,获得积分10
18秒前
20秒前
赵雪完成签到 ,获得积分10
20秒前
雪飞杨发布了新的文献求助10
20秒前
小蘑菇应助奇思妙想采纳,获得10
21秒前
NexusExplorer应助务实擎汉采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
On the Angular Distribution in Nuclear Reactions and Coincidence Measurements 1000
Vertébrés continentaux du Crétacé supérieur de Provence (Sud-Est de la France) 600
A complete Carnosaur Skeleton From Zigong, Sichuan- Yangchuanosaurus Hepingensis 四川自贡一完整肉食龙化石-和平永川龙 600
Le transsexualisme : étude nosographique et médico-légale (en PDF) 500
Elle ou lui ? Histoire des transsexuels en France 500
FUNDAMENTAL STUDY OF ADAPTIVE CONTROL SYSTEMS 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5310887
求助须知:如何正确求助?哪些是违规求助? 4455072
关于积分的说明 13861843
捐赠科研通 4343237
什么是DOI,文献DOI怎么找? 2384969
邀请新用户注册赠送积分活动 1379455
关于科研通互助平台的介绍 1347751